Loading…
Vanda Pharmaceuticals Inc. is projected to rise to $7.13 by 2027, a +10% move from its current price of $6.46. VNDA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $6.29 | $6.46 | $6.64 | +0.03% |
| May 30 | $6.22 | $6.46 | $6.72 | +0.07% |
| May 31 | $6.16 | $6.47 | $6.78 | +0.10% |
| Jun 1 | $6.12 | $6.47 | $6.84 | +0.13% |
| Jun 2 | $6.08 | $6.47 | $6.88 | +0.17% |
| Jun 3 | $6.05 | $6.47 | $6.93 | +0.20% |
| Jun 4 | $6.02 | $6.48 | $6.97 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.02 | $6.48 | $6.97 | +0.23% |
| Week 2 | $5.85 | $6.49 | $7.20 | +0.47% |
| Week 3 | $5.73 | $6.51 | $7.39 | +0.70% |
| Week 4 | $5.63 | $6.52 | $7.55 | +0.94% |
| Week 5 | $5.55 | $6.54 | $7.70 | +1.17% |
| Week 6 | $5.47 | $6.55 | $7.84 | +1.41% |
| Week 7 | $5.41 | $6.57 | $7.97 | +1.65% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapies to address high unmet medical needs worldwide. Its commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
VNDA is currently trading at $6.19 per share. The company has a market cap of $372.24M and is ranked 3301. The near-term price outlook is mixed, while the longer-term forecast shows notable upside with bullish sentiment in later years.
Forecasts indicate gradual upward movement over the coming years, with 2026–2029 hovering around mid-single digits and significant expansion in the 2040s and beyond. Notable long-horizon milestones include 2030 average of $8.53 (ROI 37.8%), 2040 average of $16.66 (ROI 169.1%), and 2050 average of $35.18 (ROI 468.3%), reflecting a bullish multi-year trajectory.
A major floor 21.1% below — a decisive break under it would weaken the trend.
The nearest floor, 7.3% below — buyers have tended to step in here.
The nearest ceiling, 17.0% above — a clean break opens room to run.
A major ceiling 48.0% above — clearing it would confirm fresh momentum.
Key VNDA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VNDA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.25 | Buy | $6.29 | Buy |
| MA 10 | $6.24 | Buy | $6.32 | Buy |
| MA 20 | $6.57 | Sell | $6.48 | Sell |
| MA 50 | $6.94 | Sell | $6.84 | Sell |
| MA 100 | $7.36 | Sell | $6.88 | Sell |
| MA 200 | $6.27 | Buy | $6.45 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.60 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -17.15 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 2.87 | Buy |
| Bollinger %B (20,2) | 0.44 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.52 | Sell |
| Awesome (5,34) | -0.51 | Sell |
| Ultimate (7,14,28) | 49.19 | Neutral |
| Momentum (10) | 0.04 | Buy |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 6.29 | Buy |
| ADX (14) | 18.38 | Neutral |
| ATR (14) | 0.15 | Info |
The 30-day technical picture shows sentiment NEUTRAL, with RSI14 at 40, and moving averages positioned at sma50 $7.04 and sma200 $6.25. Support is $5.99 and resistance is $7.56, with a 30-day price range of $5.14 to $7.46.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.76 | $6.46 | $8.50 | 0% | Neutral | |
| $5.65 | $7.13 | $9.55 | +10% | Neutral | |
| $5.95 | $7.72 | $10.72 | +20% | Neutral | |
| $5.56 | $7.38 | $10.54 | +14% | Neutral | |
| $6.75 | $9.15 | $13.39 | +42% | Bullish | |
| $8.25 | $11.39 | $17.02 | +76% | Bullish | |
| $8.00 | $11.25 | $17.13 | +74% | Bullish | |
| $8.42 | $12.03 | $18.65 | +86% | Bullish | |
| $8.48 | $12.32 | $19.39 | +91% | Bullish | |
| $8.40 | $12.38 | $19.78 | +92% | Bullish | |
| $11.77 | $18.58 | $31.58 | +188% | Bullish | |
| $22.08 | $39.19 | $72.93 | +507% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.76 | $6.46 | $7.58 | +0.00% |
| June 2026 | $5.59 | $6.57 | $7.90 | +1.65% |
| July 2026 | $5.62 | $6.66 | $8.12 | +1.41% |
| August 2026 | $5.43 | $6.48 | $7.98 | -2.74% |
| September 2026 | $5.35 | $6.42 | $7.98 | -0.89% |
| October 2026 | $5.51 | $6.64 | $8.32 | +3.49% |
| November 2026 | $5.56 | $6.73 | $8.49 | +1.37% |
| December 2026 | $5.51 | $6.70 | $8.50 | -0.56% |
Click any year to see its month-by-month VNDA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, VNDA is projected to trade between $5.76 and $8.50, averaging $6.46 — a potential gain of 0% from today's $6.46. Price action looks broadly range-bound.
Vanda Pharmaceuticals Inc.'s 2027 outlook centres on $7.13, within a $5.65 to $9.55 range. That is up +10% on the projected 2026 average. That marks a +10% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, VNDA could reach as high as $10.72, with a base case around $7.72 and support toward $5.95 — roughly +20% from $6.46. Price action looks broadly range-bound.
Expect VNDA to range from $5.56 to $10.54 through 2029. The $7.38 average target implies a +14% move from current prices. That is -4% versus the projected 2028 average. A consolidation phase looks the most probable path here.
The VNDA price prediction for 2030 points to an average of $9.15 (low $6.75, high $13.39) — a potential gain of +42% on today's $6.46. Momentum favours further upside here.
In 2031, VNDA is projected to trade between $8.25 and $17.02, averaging $11.39 — a potential gain of +76% from today's $6.46. That is up +24% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Vanda Pharmaceuticals Inc.'s 2032 outlook centres on $11.25, within a $8.00 to $17.13 range. That is -1% versus the projected 2031 average. That marks a +74% change versus current levels. Momentum favours further upside here.
By 2033, VNDA could reach as high as $18.65, with a base case around $12.03 and support toward $8.42 — roughly +86% from $6.46. Buyers look set to stay in control over this stretch.
Expect VNDA to range from $8.48 to $19.39 through 2034. The $12.32 average target implies a +91% move from current prices. That is up +2% on the projected 2033 average. Momentum favours further upside here.
The VNDA price prediction for 2035 points to an average of $12.38 (low $8.40, high $19.78) — a potential gain of +92% on today's $6.46. Buyers look set to stay in control over this stretch.
In 2040, VNDA is projected to trade between $11.77 and $31.58, averaging $18.58 — a potential gain of +188% from today's $6.46. That is up +50% on the projected 2035 average. Momentum favours further upside here.
Vanda Pharmaceuticals Inc.'s 2050 outlook centres on $39.19, within a $22.08 to $72.93 range. That is up +111% on the projected 2040 average. That marks a +507% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in VNDA today (≈ 154.798762 VNDA) could be worth
$6,066.29
+$5,066.29 (+507%) by 2050 · US Dollar
Based on the average projected VNDA price of $39.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VNDAwould be worth at today's price.
$1,000 invested in VNDA on May 27, 2025 (≈ 230.946886 VNDA) would be worth
$1,491.92
+$491.92 (+49.2%) today · 1.49× · US Dollar
Based on a VNDA entry price of $4.33 vs. today's $6.46.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.18 | $1,045.31 | +4.5% |
| 1 month ago | $6.79 | $951.4 | -4.9% |
| 3 months ago | $8.6 | $751.16 | -24.9% |
| 6 months ago | $5.36 | $1,205.22 | +20.5% |
| 1 year ago | $4.33 | $1,491.92 | +49.2% |
| All time (5.0y) ago | $17.81 | $362.72 | -63.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VNDA forecast.
Our base-case forecast reaches $13.00 around 2040.
Implied market cap at $13.00: $781.76M
Over the multi-year horizon, the forecast shows bullish sentiment accelerating in 2030 and beyond. The 2030 average is $8.53 with ROI of 37.8%. The 2040 forecast is $16.66 on average, with ROI of 169.1%.
The 2050 forecast places the average at $35.18 and ROI at 468.3%. These figures imply meaningful upside over time, though they are estimates and not guarantees. The outlook depends on factors such as sustained development and market adoption of therapies and is subject to regulatory, competitive, and clinical outcomes that could alter the path.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $8.53, with a min of $6.26 and a max of $12.54, and ROI of 37.8% with a bullish sentiment.
Forecasts show bullish sentiment in 2030 and beyond (2030 avg $8.53; 2040 avg $16.66; 2050 avg $35.18 with rising ROI), but near-term years (2026–2029) are neutral to mixed. ROI figures are estimates, not guarantees.
The forecast max in 2050 is $65.99, indicating a ceiling around that level according to the projected path.
RSI14 is 40 with neutral sentiment. The 30-day range is $5.14 to $7.46, support at $5.99, and resistance at $7.56.
Vanda Pharmaceuticals Inc. Community Discussion
0Share your Vanda Pharmaceuticals Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.